Effect of Carnosine on Diabetes and Cardiovascular Risk Factors (Carnorisk)

Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors

Carnosine is a naturally occurring compound with a potential health benefits. In animal studies, carnosine supplementation reduces manifestation of chronic civilization diseases, regulates subclinical inflammation, protein glycation and lipid & glucose metabolism. Our preliminary data showed the relationship between insulin resistance and carnosine content in human skeletal muscle. Based on these unique results we plan to perform intervention study aimed at identifying effects of carnosine on insulin sensitivity and secretion, which might reduce the development of T2D in obese. Similar metabolic effects of vitamin D3 were associated with expression of specific miRNAs. Circulating miRNAs related to carnosine action are unknown. The putative positive effects of carnosine on insulin sensitivity and secretion in obese patients might have a tremendous impact in prevention of type 2 diabetes. Identification of miRNAs associated with carnosine action could provide predictors of successful therapy.

detected by the oral glucose tolerance test. expressed as 2h glucose, area under the glycemic curve, QUICKI index, HOMA-IR

assessed by 1H-MRS of muscle in vivo (7T Magnet, Siemens, Germany) it will be expressed relative to creatine signal.

Inclusion Criteria: BMI (28-38 kg.m-2); waist circumference >94 cm; % body fat 30% fasting glycemia < 7 mmol/l Exclusion Criteria: age < 25 or > 50 years, change in body weight > 5 kg in last 12 months, obesity with BMI > 38kg.m-2, previously or newly (oGTT) diagnosed type 2 diabetes, allergy, smoking, alcohol abuse, any pharmacotherapy including regular vitamin intake; cardiovascular, hematologic, respiratory, gastrointestinal, endocrine or oncologic diseases, kidney disease, acute inflammatory disease.